After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more

489
29
Favorite

After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more

StreetInsider2022-01-27

After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

489

Report

Comment（29）

time to eat
·2022-01-27
Just buy
Reply
1
Report
VivianChua
·2022-01-27
Tesla💚Nice day
Reply
2
Report
JLKang
·2022-01-27
Tesla seems good
Reply
1
Report
小虎一飞冲天
·2022-01-27
Like pls.
Reply
3
Report
angelo0908
·2022-01-27
Good
Reply
2
Report
WaiSiong81
·2022-01-27
👍
Reply
1
Report
Steven Tay
·2022-01-27
Ok
Reply
2
Report
SQP
·2022-01-27
💪💪💪
Reply
1
Report
TaiWoeiHaur
·2022-01-27
Good morning
Reply
3
Report
LennartM
·2022-01-27
like pls
Reply
5
Report
Shot
·2022-01-27
Up and down
Reply
3
Report
Universe宇宙
·2022-01-27
After-Hours Stock Movers:$Epizyme(EPZM)$$LendingClub(LC)$$ServiceNow(NOW)$
Reply
3
Report
PearlynCSY
·2022-01-27
The Federal Reserve on Wednesday provided the clearest hint yet that it could start raising interest rates as soon as March. Fed Chairman Jerome Powell said asset purchases also are likely to halt in March. All three major indexes are decidedly negative in January. The Nasdaq is in correction territory, down more than 16% from its intraday high and off 13% for the month. The S&P 500 is down more than 8% to start the year and nearly 10% off its high.
Reply
5
Report
D6655
·2022-01-27
Tesla is still strong
Reply
6
Report
Oyh
·2022-01-27
Ok
Reply
2
Report
Dennyeo
·2022-01-27
Ok
Reply
2
Report
Ah Deck
·2022-01-27
Market is still weak
Reply
2
Report
SSVC
·2022-01-27
K
Reply
5
Report
Fionfion82
·2022-01-27
Like
Reply
3
Report
Greg2021
·2022-01-27
Go TSLA
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2206892839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-27 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2206892839","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NOW","symbol_name":"ServiceNow","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","article_id":"2206892839","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","pubTimestamp":1643237880,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NOW":"ServiceNow","BK4097":"系统软件","BK4166":"消费信贷","NFLX":"奈飞","BK4139":"生物科技","ZYME":"ZYMEWORKS INC (US)","XM":"Qualtrics International","TSLA":"特斯拉","INTC":"英特尔","BK4503":"景林资产持仓","LRCX":"拉姆研究","CNC":"康西哥","BK4524":"宅经济概念","LC":"LendingClub","BK4551":"寇图资本持仓","EPZM":"Epizyme Inc.","BK4108":"电影和娱乐","EW":"爱德华兹"},"translate_title":"盘后股票市场：泰斯拉、英特尔、Netflix,Inc.、ServiceNow、Lam Research、Epizyme等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":1,"XM":1,"NOW":1,"NFLX":1,"LC":1,"EPZM":1,"EW":0.9,"TSLA":0.9,"LRCX":0.9,"INTC":0.9,"CNC":0.9},"content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9090710337,"gmtCreate":1643263548751,"gmtModify":1676533792041,"author":{"id":"3583412008066274","authorId":"3583412008066274","name":"time to eat","avatar":"https://static.tigerbbs.com/c3d6a537cecde2d1daeefa1dd8ff6f99","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3583412008066274","authorIdStr":"3583412008066274"},"htmlText":"Just buy","listText":"Just buy","text":"Just buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090710337","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090799490,"gmtCreate":1643258112815,"gmtModify":1676533791563,"author":{"id":"3580011914778910","authorId":"3580011914778910","name":"VivianChua","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3580011914778910","authorIdStr":"3580011914778910"},"htmlText":"Tesla💚Nice day","listText":"Tesla💚Nice day","text":"Tesla💚Nice day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090799490","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090476057,"gmtCreate":1643253872001,"gmtModify":1676533791097,"author":{"id":"4094622337222610","authorId":"4094622337222610","name":"JLKang","avatar":"https://static.tigerbbs.com/33ab643c577c9cadc6055155d6382c3a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094622337222610","authorIdStr":"4094622337222610"},"htmlText":"Tesla seems good&nbsp;","listText":"Tesla seems good&nbsp;","text":"Tesla seems good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090476057","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090447502,"gmtCreate":1643252433374,"gmtModify":1676533790977,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582098623642517","authorIdStr":"3582098623642517"},"htmlText":"Like pls.","listText":"Like pls.","text":"Like pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090447502","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090448072,"gmtCreate":1643251015690,"gmtModify":1676533790841,"author":{"id":"4097296316103040","authorId":"4097296316103040","name":"angelo0908","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4097296316103040","authorIdStr":"4097296316103040"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090448072","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090441294,"gmtCreate":1643250962139,"gmtModify":1676533790825,"author":{"id":"4092698747642690","authorId":"4092698747642690","name":"WaiSiong81","avatar":"https://static.tigerbbs.com/81c10c8d3ad2387a719eaa62a541371f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092698747642690","authorIdStr":"4092698747642690"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090441294","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090443750,"gmtCreate":1643250829907,"gmtModify":1676533790824,"author":{"id":"4099285253763630","authorId":"4099285253763630","name":"Steven Tay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4099285253763630","authorIdStr":"4099285253763630"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090443750","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090449103,"gmtCreate":1643250542908,"gmtModify":1676533790766,"author":{"id":"4104824376193480","authorId":"4104824376193480","name":"SQP","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4104824376193480","authorIdStr":"4104824376193480"},"htmlText":"💪💪💪","listText":"💪💪💪","text":"💪💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090449103","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090457797,"gmtCreate":1643250297122,"gmtModify":1676533790734,"author":{"id":"3563667765668803","authorId":"3563667765668803","name":"TaiWoeiHaur","avatar":"https://community-static.tradeup.com/news/4573ecee7a4a891ace3e5566a59069d5","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3563667765668803","authorIdStr":"3563667765668803"},"htmlText":"Good morning&nbsp;","listText":"Good morning&nbsp;","text":"Good morning","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090457797","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090454379,"gmtCreate":1643249873580,"gmtModify":1676533790693,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3576017931077934","authorIdStr":"3576017931077934"},"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090454379","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090424852,"gmtCreate":1643247949915,"gmtModify":1676533790302,"author":{"id":"4105783656507550","authorId":"4105783656507550","name":"Shot","avatar":"https://community-static.tradeup.com/news/3bf75a96475b9f4c635e978fbb44e2a6","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4105783656507550","authorIdStr":"4105783656507550"},"htmlText":"Up and down","listText":"Up and down","text":"Up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090424852","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090423121,"gmtCreate":1643246992676,"gmtModify":1676533790172,"author":{"id":"3585001294737518","authorId":"3585001294737518","name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":6,"crmLevelSwitch":0,"idStr":"3585001294737518","authorIdStr":"3585001294737518"},"htmlText":"After-Hours Stock Movers:<a href=\"https://ttm.financial/S/EPZM\">$Epizyme(EPZM)$</a><a href=\"https://ttm.financial/S/LC\">$LendingClub(LC)$</a><a href=\"https://ttm.financial/S/NOW\">$ServiceNow(NOW)$</a>","listText":"After-Hours Stock Movers:<a href=\"https://ttm.financial/S/EPZM\">$Epizyme(EPZM)$</a><a href=\"https://ttm.financial/S/LC\">$LendingClub(LC)$</a><a href=\"https://ttm.financial/S/NOW\">$ServiceNow(NOW)$</a>","text":"After-Hours Stock Movers:$Epizyme(EPZM)$$LendingClub(LC)$$ServiceNow(NOW)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090423121","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090482141,"gmtCreate":1643245362273,"gmtModify":1676533789747,"author":{"id":"4092458811577680","authorId":"4092458811577680","name":"PearlynCSY","avatar":"https://static.tigerbbs.com/b3e9fe7af061efe80a756d23de62e7b3","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"4092458811577680","authorIdStr":"4092458811577680"},"htmlText":"The Federal Reserve on Wednesday provided the clearest hint yet that it could start raising interest rates as soon as March. Fed Chairman Jerome Powell said asset purchases also are likely to halt in March. All three major indexes are decidedly negative in January. The Nasdaq is in correction territory, down more than 16% from its intraday high and off 13% for the month. The S&amp;P 500 is down more than 8% to start the year and nearly 10% off its high.","listText":"The Federal Reserve on Wednesday provided the clearest hint yet that it could start raising interest rates as soon as March. Fed Chairman Jerome Powell said asset purchases also are likely to halt in March. All three major indexes are decidedly negative in January. The Nasdaq is in correction territory, down more than 16% from its intraday high and off 13% for the month. The S&amp;P 500 is down more than 8% to start the year and nearly 10% off its high.","text":"The Federal Reserve on Wednesday provided the clearest hint yet that it could start raising interest rates as soon as March. Fed Chairman Jerome Powell said asset purchases also are likely to halt in March. All three major indexes are decidedly negative in January. The Nasdaq is in correction territory, down more than 16% from its intraday high and off 13% for the month. The S&P 500 is down more than 8% to start the year and nearly 10% off its high.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090482141","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090483820,"gmtCreate":1643244776891,"gmtModify":1676533789660,"author":{"id":"4100748762151010","authorId":"4100748762151010","name":"D6655","avatar":"https://static.itradeup.com/news/bbe8f54ea256ffcc526f67f2ffb59f2d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4100748762151010","authorIdStr":"4100748762151010"},"htmlText":"Tesla is still strong&nbsp;","listText":"Tesla is still strong&nbsp;","text":"Tesla is still strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090483820","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090483385,"gmtCreate":1643244763577,"gmtModify":1676533789659,"author":{"id":"3561459567222461","authorId":"3561459567222461","name":"Oyh","avatar":"https://community-static.tradeup.com/news/6efe76978b8678e18a4d96fd589746dd","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3561459567222461","authorIdStr":"3561459567222461"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090483385","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090417123,"gmtCreate":1643244367009,"gmtModify":1676533789588,"author":{"id":"3582021832486442","authorId":"3582021832486442","name":"Dennyeo","avatar":"https://static.tigerbbs.com/25b7d84fd64f134409a4350c85c88965","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582021832486442","authorIdStr":"3582021832486442"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090417123","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090416574,"gmtCreate":1643244062455,"gmtModify":1676533789524,"author":{"id":"4098445225447010","authorId":"4098445225447010","name":"Ah Deck","avatar":"https://static.tigerbbs.com/0e52eb1e14e0f630d24f1687ea546cd8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4098445225447010","authorIdStr":"4098445225447010"},"htmlText":"Market is still weak&nbsp;","listText":"Market is still weak&nbsp;","text":"Market is still weak","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090416574","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090411228,"gmtCreate":1643243909780,"gmtModify":1676533789452,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090411228","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090413942,"gmtCreate":1643243760193,"gmtModify":1676533789419,"author":{"id":"3567652695695694","authorId":"3567652695695694","name":"Fionfion82","avatar":"https://static.tigerbbs.com/22ca6345985b52ec868cac92aafafdc1","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3567652695695694","authorIdStr":"3567652695695694"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090413942","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9090419637,"gmtCreate":1643243683308,"gmtModify":1676533789394,"author":{"id":"3568957285760850","authorId":"3568957285760850","name":"Greg2021","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":6,"crmLevelSwitch":1,"idStr":"3568957285760850","authorIdStr":"3568957285760850"},"htmlText":"Go TSLA&nbsp;","listText":"Go TSLA&nbsp;","text":"Go TSLA","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9090419637","repostId":2206892839,"repostType":4,"repost":{"id":"2206892839","pubTimestamp":1643237880,"share":"https://ttm.financial/m/news/2206892839?lang=&edition=fundamental","pubTime":"2022-01-27 06:58","market":"us","language":"en","title":"After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2206892839","media":"StreetInsider","summary":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offe","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.</p><p><a href=\"https://laohu8.com/S/LC\">LendingClub</a> (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.</p><p><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a> (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.</p><p><a href=\"https://laohu8.com/S/ZYME\">Zymeworks Inc.</a> (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.</p><p><a href=\"https://laohu8.com/S/XM\">Qualtrics International</a> (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.</p><p><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.</p><p>Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.</p><p>Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.</p><p>Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.</p><p>Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.</p><p>Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.</p><p>Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.</p><p>Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.</p><p>Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Tesla, Intel, Netflix, ServiceNow, Lam Research, Epizyme and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-27 06:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19510717><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19510717\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","EW":"爱德华兹","TSLA":"特斯拉","BK4503":"景林资产持仓","INTC":"英特尔","BK4166":"消费信贷","CNC":"康西哥","BK4524":"宅经济概念","BK4551":"寇图资本持仓","NOW":"ServiceNow","NFLX":"奈飞","XM":"Qualtrics International","ZYME":"ZYMEWORKS INC (US)","BK4108":"电影和娱乐","LRCX":"拉姆研究","BK4097":"系统软件","EPZM":"Epizyme Inc.","LC":"LendingClub"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19510717","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2206892839","content_text":"After-Hours Stock Movers:Epizyme, Inc. (Nasdaq: EPZM) 25.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.LendingClub (NYSE: LC) 12.6% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.Qualtrics International (NASDAQ: XM) 15.7% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.Flex Ltd. (NASDAQ: FLEX) 6.4% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.Levi (NYSE: LEVI) 7.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.Lam Research (NASDAQ: LRCX) 5.6% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.Centene (NYSE: CNC) 4.3% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.Netflix (NASDAQ: NFLX) 5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.Intel (NASDAQ: INTC) 1.8% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.Tesla (NASDAQ: TSLA) 0.5% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":489,"commentSize":29,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}